Biomarkers for early detection of diabetic nephropathy | 48640

Primary Health Care: Open Access

ISSN - 2167-1079

Biomarkers for early detection of diabetic nephropathy

Annual Congress & Medicare Expo on Primary Healthcare

April 25-27, 2016 Dubai, UAE

El Metwally Lotfy El Shahawy

Banha University, Egypt

Posters & Accepted Abstracts: Primary Health Care

Abstract :

Diabetes mellitus is a chronic disease that affects 366 million people worldwide (6.4% of the adult population) and is expected to rise to 552 million by 2030. Diabetes is the most frequent cause of ESRD in developed countries, (25ΓΆΒ?Β?40% of incident patients). Diabetic nephropathy (DN), defined as albuminuria (albumin excretion rate > 300 mg/24 h) and declining renal function in a patient with known diabetes in the absence of urinary tract infection or any other renal disease. The Classic pattern of Diabetic Nephropathy: ΓΆΒ?ΒΆ Initial Microalbuminuria (urinary albumin excretion rate [UAER] 30ΓΆΒ?Β?300 mg/24 h) ΓΆΒ?ΒΆ Macroalbuminuria (UAER ΓΆΒ?Β¥300 mg/24 h) ΓΆΒ?ΒΆ Progressive decrease in renal function leading to ESRD Microalbuminuria is the gold standard for detection and prediction of diabetic kidney disease and cardiovascular risk disease in clinical practice. However, microalbuminuria has several limitations, such as lower sensitive, larger variability. It is urgent to explore higher sensitivity and specificity for earlier detection of diabetic nephropathy and more accurate prediction of the progression to end stage renal disease. I will review some new and important biomarkers, such as: Markers of Glomerular Dysfunction, Markers of Tubular Dysfunction, Markers of Oxidative Stress and Inflammation, Genetic Factors, Proteomics and Metabolomics.

Biography :